References:

Disclosure of Interests: Gaia Mancuso: None declared, Emanuel Della Torre: None declared, Marco Lanzillotta: None declared, Giuseppe Alivise Ramirez: None declared, Lorenzo Dagna Grant/research support from: The Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UNIR) RRAI received unrestricted research/educational grants from Abbvie, Bristol-Myers Squibb, Celgene, Janssen, Merk Sharp & Dohme, Mundipharma Pharmaceuticals, Novartis, Pfizer, Roche, Sanofi-Genzyme, and SOBI. Consultant of: Prof Lorenzo Dagna received consultation honoraria from Abbvie, Amgen, Biogen, Bristol-Myers Squibb, Celtrion, Novartis, Pfizer, Roche, Sanofi-Genzyme, and SOBI.

DOI: 10.1136/annrheumdis-2020-eular.2919

AB1048
RHPUS SYNDROME IN A TERTIARY HOSPITAL
I. Martínez Cordelat1, R. González Mazaró2, M. De la Rubia Navarro3, C. Páez Perales1, S. Leal Rodriguez1, J. Ivorra Cortés1, I. Cánovas Olmos1, J. A. Román L. Arnaud1, T. Martin2.

Disclosure of Interests: None declared, Emanuel Della Torre: None declared, Marco Lanzillotta: None declared, Giuseppe Alivise Ramirez: None declared, Lorenzo Dagna: None declared, Lorenzo Dagna: None declared, Lorenzo Dagna: None declared, Lorenzo Dagna: None declared, Lorenzo Dagna: None declared, Lorenzo Dagna: None declared, Lorenzo Dagna: None declared, Lorenzo Dagna: None declared.

AB1050
CLINICAL IMPLICATIONS OF ULTRASONOGRAPHY (US) IN DIAGNOSIS AND MONITORING DISEASE ACTIVITY OF RELAPSING POLYCHONDRIITIS (RP) AND COMPARATIVE INVESTIGATION BY US BETWEEN AURICLE OF RP, REPEATED TRAUMA, CELLULITIS AND HEALTHY SUBJECT
H. Nishioka1, Y. Taniguchi1, M. Ogawasara1, S. Inotani1, E. Amano1, T. Matsumoto1, K. Hamada-Ode1, Y. Shimamura1, T. Horino1, S. Fujimoto1, Y. Terada1, K. Ito2, H. K. Min3.

Disclosure of Interests: None declared, Emilie Chalayer: None declared, Jean Sibilia: None declared, Jacques-Eric Gottenberg: None declared, AIMF, but a high rate of GC dependency and long-term complications indicate the need to find new sparing drugs.

Disclosure of Interests: PHILIPPE MERTZ: None declared, Emilie Chalayer: None declared, Jean Sibilia: None declared, Jacques-Eric Gottenberg: None declared, AIMF, but a high rate of GC dependency and long-term complications indicate the need to find new sparing drugs.

Disclosure of Interests: None declared, Emilie Chalayer: None declared, Jean Sibilia: None declared, Jacques-Eric Gottenberg: None declared, AIMF, but a high rate of GC dependency and long-term complications indicate the need to find new sparing drugs.

Disclosure of Interests: None declared, Emilie Chalayer: None declared, Jean Sibilia: None declared, Jacques-Eric Gottenberg: None declared, AIMF, but a high rate of GC dependency and long-term complications indicate the need to find new sparing drugs.

Disclosure of Interests: None declared, Emilie Chalayer: None declared, Jean Sibilia: None declared, Jacques-Eric Gottenberg: None declared, AIMF, but a high rate of GC dependency and long-term complications indicate the need to find new sparing drugs.

Disclosure of Interests: None declared, Emilie Chalayer: None declared, Jean Sibilia: None declared, Jacques-Eric Gottenberg: None declared, AIMF, but a high rate of GC dependency and long-term complications indicate the need to find new sparing drugs.

Disclosure of Interests: None declared, Emilie Chalayer: None declared, Jean Sibilia: None declared, Jacques-Eric Gottenberg: None declared, AIMF, but a high rate of GC dependency and long-term complications indicate the need to find new sparing drugs.

Disclosure of Interests: None declared, Emilie Chalayer: None declared, Jean Sibilia: None declared, Jacques-Eric Gottenberg: None declared, AIMF, but a high rate of GC dependency and long-term complications indicate the need to find new sparing drugs.

Disclosure of Interests: None declared, Emilie Chalayer: None declared, Jean Sibilia: None declared, Jacques-Eric Gottenberg: None declared, AIMF, but a high rate of GC dependency and long-term complications indicate the need to find new sparing drugs.

Disclosure of Interests: None declared, Emilie Chalayer: None declared, Jean Sibilia: None declared, Jacques-Eric Gottenberg: None declared, AIMF, but a high rate of GC dependency and long-term complications indicate the need to find new sparing drugs.

Disclosure of Interests: None declared, Emilie Chalayer: None declared, Jean Sibilia: None declared, Jacques-Eric Gottenberg: None declared, AIMF, but a high rate of GC dependency and long-term complications indicate the need to find new sparing drugs.

Disclosure of Interests: None declared, Emilie Chalayer: None declared, Jean Sibilia: None declared, Jacques-Eric Gottenberg: None declared, AIMF, but a high rate of GC dependency and long-term complications indicate the need to find new sparing drugs.

Disclosure of Interests: None declared, Emilie Chalayer: None declared, Jean Sibilia: None declared, Jacques-Eric Gottenberg: None declared, AIMF, but a high rate of GC dependency and long-term complications indicate the need to find new sparing drugs.

Disclosure of Interests: None declared, Emilie Chalayer: None declared, Jean Sibilia: None declared, Jacques-Eric Gottenberg: None declared, AIMF, but a high rate of GC dependency and long-term complications indicate the need to find new sparing drugs.

Disclosure of Interests: None declared, Emilie Chalayer: None declared, Jean Sibilia: None declared, Jacques-Eric Gottenberg: None declared, AIMF, but a high rate of GC dependency and long-term complications indicate the need to find new sparing drugs.

Disclosure of Interests: None declared, Emilie Chalayer: None declared, Jean Sibilia: None declared, Jacques-Eric Gottenberg: None declared, AIMF, but a high rate of GC dependency and long-term complications indicate the need to find new sparing drugs.

Disclosure of Interests: None declared, Emilie Chalayer: None declared, Jean Sibilia: None declared, Jacques-Eric Gottenberg: None declared, AIMF, but a high rate of GC dependency and long-term complications indicate the need to find new sparing drugs.